Skip to content

COMPASS THERAPEUTICS, INC.

CMPX

CIK 0001738021

← back to feed
Revenue (TTM)
$850K
−100.0% YoY Q1 Apr 2026
Net Income (TTM)
−$69.09M
−34.7% YoY Q1 Apr 2026
EPS Diluted (TTM)
—
Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-8,840.9%
Q1 Apr 2026
Net Margin
-8,128.2%
Q1 Apr 2026
Free Cash Flow (TTM)
−$56.69M
Q1 Apr 2026
Cash
$55.17M
Q1 Apr 2026
Total Debt
$0
Q1 Apr 2026
Shares Outstanding
180.09M sh
Q1 Apr 2026

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings